Compounds for treating viral infections
AssigneeInstitut Pasteur Korea
InventorsMarc P. Windisch, Hee-Young Kim, Jaewon Yang, Jong Yeon Hwang, Suyeon Jo, Jeongjin Kwon, Dongsik Park, Jihyun Choi, Jaeheon Lee
Life of this patent
Estimating the term…
Abstract
The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).
Claims17
A compound having Formula (If):
- wherein
- RD is selected from the group consisting of halo;
- cyano;
- C1-C5 alkyl;
- C3-C6 cycloalkyl;
- C1-C3 alkoxy;
- C1-C3 haloalkyl;
- C1-C3 sulfanyl;
- phenyl;
- aryl;
- heteroaryl;
- —NRGRH;
- —C(O)NRaRb;
- —C(O)Rc;
- —C(O)ORc;
- sulfonyl;
- sulfoxide;
- RO and RP are each independently at each occurrence selected from the group consisting of H, C1-C5 alkyl, C1-C5 alkenyl, C1-C5 alkynyl, C3-C6 cycloalkyl;
- heterocycloalkyl;
- heteroaryl;
- phenyl;
- with either the proviso that, when one of RO or RP is H, then the other one of RO or RP is not methyl;
- or with the proviso that the compound is not;
- RO and RP are joined together, forming a cycloalkyl group, cycloalkenyl group, or heterocycloalkyl group optionally substituted with one to four RI groups;
- wherein RI is selected from the group consisting of H;
- halo;
- cyano;
- C1-C5 alkyl;
- C1-C3 sulfanyl;
- C1-C4 alkoxy;
- C1-C3 haloalkyl;
- hydroxyl;
- oxo;
- —NRaRb;
- —C(O)NRaRb;
- —C(O)Rc;
- —C(O)ORc;
- sulfonyl;
- sulfoxide;
- (CH2)pOH;
- (CH2)pORa;
- (CH2)pNRGRH;
- (CH2)pOC(O)NRaRb;
- (CH2)pC(O)NRaRb;
- C3-C6 cycloalkyl;
- heterocycloalkyl;
- aryl;
- heteroaryl;
- phenyl;
- RG is selected from the group consisting of H;
- C1-C6 alkyl;
- C1-C6 alkoxy;
- C3-C6 cycloalkyl;
- heterocycloalkyl;
- heteroaryl;
- phenyl;
- RH is selected from the group consisting of H;
- C1-C6 alkyl;
- C1-C6 alkoxy;
- C3-C6 cycloalkyl;
- heterocycloalkyl;
- heteroaryl;
- phenyl;
- or
- RG and RH, together with the nitrogen atom to which they are bonded, form a 4- to 10-membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C1-C3 alkyl, benzyl, phenyl, C1-C3 alkoxy or halogen;
- RC is selected from C1-C10 alkyl, C1-C10 alkenyl, C1-C10 alkynyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, aryl, heteroaryl, heterocycloalkyl, wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl may be substituted with one or more of hydroxyl, halo, alkoxy, oxo, sulfonyl, sulfoxide, aryl, heteroaryl or —NRaRb;
- RM is selected from the group consisting of H;
- C1-C6 alkyl, C3-C6 cycloalkyl, C1-C3 haloalkyl, phenyl;
- aryl;
- heteroaryl;
- —NRGRH;
- —C(O)NRaRb;
- —C(O)Rc;
- —C(O)ORc;
- sulfonyl;
- sulfoxide;
- C1-C6 alkyl substituted with hydroxyl, alkoxy, —NRaRb, phenyl, —NRGRH, —C(O)NRaRb, —C(O)Rc, —C(O)ORc;
- sulfonyl, or sulfoxide;
- RQ and RR represents a substituent which is at each occurrence independently selected from the group consisting of H;
- halo;
- cyano;
- C1-C5 alkyl;
- C3-C6 cycloalkyl;
- C1-C3 alkoxy;
- C1-C3 haloalkyl;
- C1-C3 sulfanyl;
- phenyl;
- aryl;
- heteroaryl;
- —NRGRH;
- —C(O)NRaRb;
- —C(O)Rc;
- —C(O)ORc;
- sulfonyl;
- sulfoxide;
- (CH2)pOH;
- (CH2)pORa;
- (CH2)pNRGRH;
- (CH2)pOC(O)NRaRb;
- (CH2)pC(O)NRaRb;
- Ra and Rb are each independently at each occurrence selected from the group consisting of hydrogen, C1-C6 alkyl, substituted C1-C6 alkyl, C1-C6 alkoxyC1-C6 alkyl, C6-C14 alkyl chain containing one or several of —O—, —C(O)NH—, —NHC(O)—, —N—, or —NHC(O)O— optionally with a terminal —NH2 or —NH-Boc;
- C1-C6 alkenyl, substituted C1-C6 alkenyl, C1-C6 alkynyl, substituted C1-C6 alkynyl, C3-C7 cycloalkyl, substituted C3-C7 cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl;
- or
- Ra and Rb, together with the nitrogen atom to which they are bonded, form a 4- to 10-membered saturated or unsaturated heterocyclic ring which is optionally substituted with one or more C1-C3 alkyl, benzyl, phenyl, C1-C3 alkoxy or halogen;
- Rc is selected from the group consisting of hydrogen, C1-C10, C1-C10 alkenyl, C1-C10 alkynyl, C3-C10 cycloalkyl, C1-C3 haloalkyl, aryl, heteroaryl, heterocycloalkyl,
- wherein each of the aforementioned alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl and heterocycloalkyl may be substituted with one or more of hydroxyl, halo, alkoxy, oxo, sulfonyl, sulfoxide, aryl, heteroaryl or —NRaRb;
- m is an integer from 0 to 2;
- k is an integer from 0 to 2;
- p is an integer from 0 to 5;
- q is an integer from 1 to 3;
- and
- r is an integer from 1 to 3,
- and pharmaceutically acceptable salts thereof.
A method of treatment of a viral disease, said method comprising the administration of a suitable amount of a compound selected from the group consisting of Formula 44, Formula 109, Formula 170, Formula 173, Formula 176, Formula 223, Formula 255, Formula 304, Formula 311, Formula 341, Formula 374, as shown below, and a pharmaceutically acceptable salt thereof, or of a composition comprising a compound selected from the group consisting of Formula 44, Formula 109, Formula 170, Formula 173, Formula 176, Formula 223, Formula 255, Formula 304, Formula 311, Formula 341, Formula 374, as shown below,
- and a pharmaceutically acceptable salt thereof to a patient in need thereof, suffering from a viral disease.
Dependencies are inferred from the claim text.